Breaking News

Paladin Labs Acquires Allon Therapeutics

July 17, 2013

Becomes the sole shareholder of Allon

Paladin Labs, Inc. has acquired Allon Therapeutics in accordance with the Order for Reorganization in Allon's proposal proceedings under Canada’s Bankruptcy and Insolvency Act and Business Corporations Act, becoming the sole shareholder of Allon.
 
In May, Allon and Paladin entered an agreement under which Paladin would obtain all outstanding shares of Allon through a reorganization of Allon's share structure and make a cash payment to Allon of $900,000.
 
Immediately prior to Paladin becoming the sole shareholder of Allon, all existing issued and outstanding shares and other securities of Allon were cancelled without payment or other consideration. As the sole shareholder of Allon, Allon will cease being a reporting issuer in Canada.

Related Contract Manufacturing:

blog comments powered by Disqus
  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • The Role of Alliances in Modern Drug Development

    The Role of Alliances in Modern Drug Development

    Dr. Claire Madden-Smith, Senior Vice President, Juniper Pharma Services||September 8, 2016
    Combining expertise to get drug candidates through development

  • Limiting APIs in Manufacturing Effluent

    Limiting APIs in Manufacturing Effluent

    Joan Tell, Robert Drinane, Bruce Naumann, Jessica Vestel, and Gregory Gagliano, Merck & Co., Inc.||June 2, 2016
    An approach for setting limits on pharmaceuticals discharged in manufacturing effluent